Prab at 13:19, 18 March 2025

2025-03-18T13:19:25Z

← Older revision		Revision as of 13:19, 18 March 2025
Line 147:		Line 147:
	{{gastrointestinal-drug-stub}}		{{gastrointestinal-drug-stub}}
	{{No image}}		{{No image}}
	~~__NOINDEX__~~

Prab: CSV import

2025-03-18T02:55:57Z

CSV import

← Older revision		Revision as of 02:55, 18 March 2025
Line 147:		Line 147:
	{{gastrointestinal-drug-stub}}		{{gastrointestinal-drug-stub}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T20:22:42Z

CSV import

← Older revision		Revision as of 20:22, 10 February 2025
Line 146:		Line 146:

	{{gastrointestinal-drug-stub}}		{{gastrointestinal-drug-stub}}
			{{No image}}

Deepika vegiraju at 13:42, 12 January 2022

2022-01-12T13:42:02Z

New page

== '''What is Taliglucerase Alfa?''' ==

* Taliglucerase Alfa (ELELYSO) is a''' hydrolytic lysosomal glucocerebroside-specific enzyme''' used to treat [[Gaucher's disease]].

<youtube>
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v/v=PMjoBaebGb8
embed_source_url=http://www.youtube.com/v/v=PMjoBaebGb8
&rel=1
wrap = yes
width=750
height=600
</youtube>

== '''What are the uses of this medicine?''' ==

* This medicine is used for the treatment of patients 4 years and older with a confirmed diagnosis of Type 1 [[Gaucher disease]].

== '''How does this medicine work?''' ==

<youtube>
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v=ZVp9oS4RqJ4
embed_source_url=http://www.youtube.com/v=ZVp9oS4RqJ4
&rel=1
wrap = yes
width=750
height=600
</youtube>

* ELELYSO, a long term enzyme replacement therapy, is a recombinant '''analog of human lysosomal glucocerebrosidase''' that '''catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside'''.
* ELELYSO uptake into cellular lysosomes is mediated by binding of ELELYSO mannose oligosaccharide chains to specific mannose receptors on the cell surface leading to internalization and subsequent transport to the lysosomes.

== '''Who Should Not Use this medicine ?''' ==

* This medicine have no usage limitations.

== '''What drug interactions can this medicine cause?''' ==

* No formal drug interaction studies have been conducted with ELELYSO.

== '''Is this medicine FDA approved?''' ==

* Taliglucerase was approved for use as enzyme replacement therapy for type 1 [[Gaucher disease]] in the United States in 2011.

== '''How should this medicine be used?''' ==

'''Recommended dosage:'''

'''Treatment-naïve patients:'''
* The recommended dosage of ELELYSO for long-term treatment is 60 units/kg of body weight administered every other week as a 60 to 120 minute intravenous infusion.

'''Patients switching from imiglucerase: '''
* Begin ELELYSO at the same unit/kg dose as the patient's previous imiglucerase dose.
* Administer ELELYSO every other week as a 60 to 120 minute intravenous infusion.
* Dosage adjustments can be based on achievement and maintenance of each patient's therapeutic goals.

'''Administration:'''
Reconstitute, dilute and administer under the supervision of a healthcare professional.
After reconstitution and dilution, the preparation should be administered via intravenous infusion and filtered through an in-line low protein-binding 0.2 μm filter.
'''For pediatric patients:'''
* An initial infusion rate of 1 mL/minute should be used.
* After tolerability to ELELYSO is established, the infusion rate may be increased, but should not exceed the maximum recommended infusion rate of 2 mL/minute. The total volume of the infusion should be delivered over a minimum of 60 minutes.
'''For adult patients: '''
* An initial infusion rate of 1.2 mL/minute should be used.
* After tolerability to ELELYSO is established, the infusion rate may be increased, but should not exceed the maximum recommended infusion rate of 2.2 mL/minute.
* The total volume of the infusion should be delivered over a minimum of 60 minutes.
* As ELELYSO contains no preservative, the product should be used immediately once reconstituted.

== '''What are the dosage forms and brand names of this medicine?''' ==

This medicine is available in fallowing doasage form:
* '''As injection:''' 200 units lyophilized powder in a single-dose vial for reconstitution

This medicine is available in fallowing brand namesː
* '''ELELYSO'''

=='''What side effects can this medication cause?'''==

The most common side effects of this medicine include:
'''In Treatment-Naïve Adults:'''
* headache
* [[arthralgia]]
* [[fatigue]]
* [[nausea]]
* [[dizziness]]
* abdominal pain
* [[pruritus]]
* flushing
* vomiting
* [[urticaria]]

In Patients Switched from Imiglucerase, after 9 Months on Treatment:
* [[arthralgia]]
* headache
* pain in extremity

==''' What special precautions should I follow?''' ==

* Serious [[hypersensitivity]] reactions, including [[anaphylaxis]], have occurred in some patients treated with ELELYSO. Observe patients during and after the infusion; immediately discontinue infusion if anaphylaxis occurs and initiate appropriate treatment. Reduction in the infusion rate and/or pre-medication may prevent subsequent reactions.

== '''What to do in case of emergency/overdose?''' ==

* {{overdose}}

== '''Can this medicine be used in pregnancy?''' ==

* The limited available data on ELELYSO use in pregnant women are not sufficient to inform a drug-associated risk.

=='''Can this medicine be used in children?'''==

* The use of ELELYSO for treatment of pediatric patients with Type 1 [[Gaucher disease]] is supported by evidence of effectiveness from adequate and well-controlled trials of ELELYSO in adults.

== '''What are the active and inactive ingredients in this medicine?''' ==

'''Active Ingredient:'''
* TALIGLUCERASE ALFA

'''Inactive Ingredients:'''
* MANNITOL
* POLYSORBATE 80
* SODIUM CITRATE, UNSPECIFIED FORM

== '''Who manufactures and distributes this medicine?''' ==

'''Manufactured by'''
* [[Pfizer]] Inc.
NY

== '''What should I know about storage and disposal of this medication?''' ==

* Store ELELYSO refrigerated at 2° C to 8° C (36° F to 46° F) in the original carton to protect from light.
* Do not freeze.

{{genetic agents}}
{{coststubd}}
{{Other alimentary tract and metabolism products}}
{{Sugar hydrolases}}
{{Enzymes}}
{{Portal bar|Biology|Medicine|border=no}}

[[Category:EC 3.2.1]]
[[Category:Israeli inventions]]

{{gastrointestinal-drug-stub}}

Taliglucerase alfa - Revision history

Prab at 13:19, 18 March 2025

Prab: CSV import

Prab: CSV import

Deepika vegiraju at 13:42, 12 January 2022